66th Annual General Meeting will be held on Wednesday, 12th August, 2026 through Video Conferencing and other audio visual means.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma's board approved FY2026 results showing revenue of Rs 7,717 lakh, up 16.6% from Rs 6,615 lakh in FY2025. However, net profit declined 13.3% to Rs 4,105 lakh (vs Rs 4,735 lakh), with EBITDA margin compressing to 8.56% from 10.64% due to higher raw material costs and forex losses. The company recommended a dividend of Rs 1.50 per share (30% payout) subject to shareholder approval at the AGM on August 12, 2026. A 1:1 bonus issue was already completed in July 2025, doubling share capital to Rs 5,011 lakh. Nine promoter group shareholders (holding 0.95% stake) have requested reclassification to the public category. Key managerial appointments include Mr. P.N. Rao as General Manager - Quality and new internal and cost auditors.
Revenue growth is positive but profit decline and margin compression may concern investors. The dividend provides income support. The promoter reclassification request could increase public shareholding, potentially improving liquidity.